Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

While aprepitant is actually recommended for the prevention of nausea and vomiting induced by a single cisplatin administration, it is still unclear whether it has a clinical benefit when administered along with daily administrations of low- dose cisplatin(20mg/m2 days 1-5). This study was conducted to evaluate the efficacy of aprepitant in patients receiving daily administration of low-dose cisplatin. Our study focused on 25 patients who received cancer therapy including cisplatin, with or without aprepitant (days 1-5). We performed a retrospective study to identify any significant positive effect of aprepitant in the prevention of nausea and vomiting for 10 days(days 1-10). Because cisplatin has a long half-life, we assessed the delayed phase nausea and vomiting(days 6-10). Multiple-day dosing of aprepitant was effective for prevention of nausea(Odds ratio: 0. 30, p= 0. 0012)and vomiting(Odds ratio: 0. 04, p=0. 0001)throughout the observation. Furthermore, we observed a significant positive effect of aprepitant in the prevention of delayed nausea(Odds ratio: 0. 19, p=0. 0083)and vomiting(Odds ratio: 0. 07, p=0. 0040). These findings suggest that multiple-day dosing of aprepitant is useful for the inhibition of acute delayed nausea and vomiting caused by chemotherapy including daily administration of low-dose cisplatin.

Citation

Misato Kariya, Kenta Tanaka, Kumiko Matsumoto, Manabu Kume, Hiroo Makimoto, Takeshi Hirano, Hideaki Miyake, Masato Fujisawa, Midori Hirai. Effects of aprepitant in daily administrations of low-dose cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy. 2012 Feb;39(2):245-50

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 22333636

View Full Text